Your browser is no longer supported. Please, upgrade your browser.
AWH Aspira Women's Health Inc. daily Stock Chart
Aspira Women's Health Inc.
Index- P/E- EPS (ttm)-0.15 Insider Own1.70% Shs Outstand98.12M Perf Week-10.96%
Market Cap274.66M Forward P/E- EPS next Y- Insider Trans124.49% Shs Float50.86M Perf Month-15.03%
Income-14.70M PEG- EPS next Q- Inst Own27.30% Short Float13.04% Perf Quarter-48.00%
Sales4.60M P/S59.71 EPS this Y-8.50% Inst Trans27.51% Short Ratio7.17 Perf Half Y251.98%
Book/sh0.07 P/B37.14 EPS next Y- ROA-109.60% Target Price- Perf Year386.89%
Cash/sh0.10 P/C25.20 EPS next 5Y- ROE-178.00% 52W Range0.35 - 5.78 Perf YTD220.99%
Dividend- P/FCF- EPS past 5Y19.90% ROI-152.80% 52W High-55.02% Beta3.24
Dividend %- Quick Ratio3.00 Sales past 5Y12.50% Gross Margin31.30% 52W Low641.59% ATR0.28
Employees52 Current Ratio3.00 Sales Q/Q-36.40% Oper. Margin- RSI (14)39.92 Volatility9.18% 9.92%
OptionableYes Debt/Eq0.30 EPS Q/Q31.00% Profit Margin- Rel Volume0.87 Prev Close2.54
ShortableYes LT Debt/Eq0.22 EarningsAug 13 AMC Payout- Avg Volume925.64K Price2.60
Recom- SMA20-7.37% SMA50-24.29% SMA20020.21% Volume799,297 Change2.36%
Sep-15-20 05:01PM  
Sep-08-20 11:44AM  
Aug-22-20 10:01AM  
Aug-14-20 03:51PM  
Aug-13-20 04:01PM  
Jul-31-20 09:23AM  
Jul-08-20 06:30AM  
Jul-01-20 11:23AM  
Jun-29-20 08:00AM  
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes diagnostic and bio-analytical solutions that help physicians to diagnose, treat, and enhance gynecologic health outcomes for women in the United States. The company provides sells OVA1, Overa, and Ova1PLUS risk of malignancy tests for ovarian cancer. It also offers ASPiRA GenetiX, a genetic test for specific women's health diseases. In addition, the company owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, it is developing diagnostic algorithms, as well as a high-risk screening algorithm for patients who are genetically predisposed to ovarian cancer. The company serves physicians, physician office laboratories, and hospital laboratories. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was founded in 1993 and is headquartered in Austin, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHREIBER DAVIDDirectorSep 08Sale2.7850,000139,000185,018Sep 10 05:35 PM
SCHULER JACK W10% OwnerJul 01Buy3.502,285,7158,000,00325,394,517Jul 06 05:25 PM
SLNO Soleno Therapeutics, Inc. daily Stock Chart
Soleno Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.62 Insider Own13.82% Shs Outstand79.59M Perf Week-9.05%
Market Cap147.79M Forward P/E- EPS next Y-0.40 Insider Trans157.62% Shs Float47.09M Perf Month-6.22%
Income-27.00M PEG- EPS next Q-0.08 Inst Own57.00% Short Float3.29% Perf Quarter-4.74%
Sales- P/S- EPS this Y-59.70% Inst Trans92.84% Short Ratio2.02 Perf Half Y-18.10%
Book/sh1.22 P/B1.48 EPS next Y0.00% ROA-60.70% Target Price- Perf Year2.84%
Cash/sh- P/C- EPS next 5Y15.00% ROE-113.00% 52W Range1.18 - 4.39 Perf YTD-38.44%
Dividend- P/FCF- EPS past 5Y38.50% ROI- 52W High-58.77% Beta0.55
Dividend %- Quick Ratio7.50 Sales past 5Y- Gross Margin- 52W Low53.39% ATR0.17
Employees12 Current Ratio7.50 Sales Q/Q- Oper. Margin- RSI (14)41.70 Volatility7.78% 8.95%
OptionableYes Debt/Eq0.00 EPS Q/Q49.30% Profit Margin- Rel Volume0.32 Prev Close1.80
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume769.22K Price1.81
Recom1.50 SMA20-10.29% SMA50-6.03% SMA200-28.65% Volume270,297 Change0.28%
Jan-10-20Initiated Craig Hallum Buy $8
Dec-23-19Initiated Oppenheimer Outperform $10
Feb-13-18Reiterated Maxim Group Buy $8 → $4
Sep-15-20 08:00AM  
Aug-20-20 08:35AM  
Aug-10-20 04:01PM  
Jul-27-20 10:09AM  
Jun-29-20 09:07AM  
Jun-26-20 04:01PM  
Jun-25-20 11:15PM  
Jun-24-20 08:31AM  
Jun-23-20 04:01PM  
Jun-15-20 08:42AM  
Jun-11-20 12:00PM  
Jun-09-20 07:46AM  
Jun-08-20 04:01PM  
Jun-01-20 08:37AM  
May-12-20 04:01PM  
Apr-23-20 08:00AM  
Mar-30-20 09:41AM  
Mar-11-20 08:00AM  
Mar-04-20 04:05PM  
Jan-20-20 04:37AM  
Jan-07-20 10:21AM  
Jan-06-20 08:00AM  
Dec-23-19 07:52PM  
Nov-13-19 08:00AM  
Oct-25-19 04:30PM  
Oct-23-19 09:00AM  
Oct-22-19 04:01PM  
Oct-02-19 08:00AM  
Oct-01-19 02:22PM  
Sep-24-19 08:00AM  
Sep-19-19 08:00AM  
Aug-07-19 04:05PM  
Jul-25-19 01:19PM  
Jul-15-19 09:00AM  
Jul-11-19 11:14AM  
Jul-01-19 08:39AM  
Jun-12-19 08:00AM  
May-28-19 06:07AM  
May-24-19 08:49AM  
May-13-19 08:00AM  
May-06-19 04:13PM  
Apr-29-19 08:00AM  
Apr-03-19 08:00AM  
Mar-27-19 08:46AM  
Mar-25-19 10:00AM  
Mar-20-19 07:48AM  
Mar-18-19 08:30AM  
Mar-15-19 04:05PM  
Mar-14-19 05:32PM  
Mar-11-19 04:05PM  
Dec-19-18 04:01PM  
Dec-12-18 06:47AM  
Nov-15-18 08:05AM  
Oct-08-18 08:00AM  
Oct-01-18 08:00AM  
Sep-19-18 08:00AM  
Sep-17-18 08:00AM  
Sep-06-18 08:00AM  
Sep-04-18 08:00AM  
Aug-14-18 04:05PM  
Jul-30-18 08:00AM  
Jun-04-18 08:00AM  
May-16-18 08:00AM  
May-14-18 08:00AM  
Apr-03-18 06:15PM  
Apr-02-18 08:00AM  
Mar-26-18 08:48PM  
Mar-16-18 06:14PM  
Feb-20-18 08:00AM  
Dec-12-17 08:30AM  
Dec-11-17 08:10AM  
Dec-08-17 05:43PM  
Nov-30-17 03:15PM  
Nov-22-17 08:00AM  
Nov-14-17 03:59PM  
Oct-23-17 08:00AM  
Oct-12-17 08:00AM  
Oct-11-17 08:00AM  
Oct-05-17 01:00PM  
Sep-25-17 08:00AM  
Sep-12-17 03:37PM  
Aug-24-17 11:22AM  
Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled Release (DCCR), a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is being evaluated in a Phase III clinical development program. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is headquartered in Redwood City, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sinclair AndrewDirectorJun 26Buy1.653,333,3305,499,99510,302,602Jul 06 04:03 PM
Abingworth LLP10% OwnerJun 26Buy1.653,333,3305,499,99510,302,602Jul 06 04:02 PM
SCHULER JACK W10% OwnerJun 26Buy1.657,575,75912,500,00211,368,862Jun 26 07:49 PM
SCHULER JACK W10% OwnerJun 10Buy1.97339,083666,8072,071,883Jun 12 08:32 PM
FEINBERG LARRY N10% OwnerJun 08Sale3.40150,918513,302655,000Jun 09 05:16 PM
FEINBERG LARRY N10% OwnerJun 05Sale3.3449,325164,578805,918Jun 09 05:16 PM
Vivo Ventures V, LLC10% OwnerDec 02Sale1.6234,02855,1253,633,805Dec 03 06:01 PM
Vivo Ventures V, LLC10% OwnerNov 27Sale1.532,8984,4343,667,833Nov 27 06:05 PM
Vivo Ventures V, LLC10% OwnerNov 26Sale1.5515,17123,5153,670,731Nov 27 06:05 PM
Vivo Ventures V, LLC10% OwnerNov 25Sale1.5614,77523,0493,685,902Nov 25 08:00 PM
Vivo Ventures V, LLC10% OwnerNov 22Sale1.552,6004,0303,700,677Nov 25 08:00 PM
Vivo Ventures V, LLC10% OwnerNov 21Sale1.5544,29668,6593,703,277Nov 25 08:00 PM
Vivo Ventures V, LLC10% OwnerNov 20Sale1.5540,92963,4403,747,573Nov 20 07:11 PM
Melincoff Gwen ADirectorNov 19Buy1.5410,00015,36410,000Nov 20 05:02 PM
Vivo Ventures V, LLC10% OwnerNov 19Sale1.556009303,788,502Nov 20 07:11 PM
Vivo Ventures V, LLC10% OwnerNov 18Sale1.551001553,789,102Nov 20 07:11 PM
Vivo Ventures V, LLC10% OwnerNov 15Sale1.5551,40479,6763,789,202Nov 15 06:53 PM
Vivo Ventures V, LLC10% OwnerNov 14Sale1.5531,39148,6563,840,606Nov 15 06:53 PM
Vivo Ventures V, LLC10% OwnerNov 13Sale1.5514,22922,0553,871,997Nov 15 06:53 PM
SCHULER JACK W10% OwnerOct 25Buy1.202,563,7503,076,5006,217,345Jun 26 07:27 PM
AXDX Accelerate Diagnostics, Inc. daily Stock Chart
Accelerate Diagnostics, Inc.
Index- P/E- EPS (ttm)-1.50 Insider Own3.70% Shs Outstand55.45M Perf Week-5.80%
Market Cap576.68M Forward P/E- EPS next Y-1.19 Insider Trans149.66% Shs Float33.25M Perf Month-22.04%
Income-82.30M PEG- EPS next Q-0.33 Inst Own52.40% Short Float44.66% Perf Quarter-19.32%
Sales10.20M P/S56.54 EPS this Y4.60% Inst Trans-2.89% Short Ratio36.90 Perf Half Y28.40%
Book/sh-0.67 P/B- EPS next Y15.00% ROA-63.70% Target Price19.00 Perf Year-50.76%
Cash/sh1.60 P/C6.50 EPS next 5Y30.00% ROE576.70% 52W Range4.53 - 21.71 Perf YTD-38.46%
Dividend- P/FCF- EPS past 5Y-16.90% ROI-59.30% 52W High-52.10% Beta2.53
Dividend %- Quick Ratio9.30 Sales past 5Y137.90% Gross Margin45.80% 52W Low129.58% ATR0.74
Employees275 Current Ratio10.10 Sales Q/Q16.70% Oper. Margin- RSI (14)34.84 Volatility5.78% 6.52%
OptionableYes Debt/Eq- EPS Q/Q9.20% Profit Margin- Rel Volume0.36 Prev Close10.70
ShortableYes LT Debt/Eq- EarningsAug 06 AMC Payout- Avg Volume402.45K Price10.40
Recom2.20 SMA20-8.03% SMA50-24.13% SMA200-19.83% Volume146,509 Change-2.80%
Aug-07-20Upgrade Craig Hallum Hold → Buy $20
Sep-27-19Downgrade JP Morgan Neutral → Underweight $16
Nov-07-18Downgrade JP Morgan Overweight → Neutral
May-24-18Initiated Craig Hallum Hold $25
Dec-13-17Downgrade BTIG Research Buy → Neutral
Jul-12-17Resumed BTIG Research Buy $34
Mar-24-16Initiated JP Morgan Overweight $17
Dec-16-15Initiated Piper Jaffray Overweight
Sep-16-20 09:00AM  
Sep-10-20 09:00AM  
Aug-24-20 09:15AM  
Aug-19-20 10:30AM  
Aug-18-20 04:15PM  
Jul-30-20 12:33PM  
Jul-17-20 07:00AM  
Jul-16-20 08:00AM  
Jun-25-20 06:26PM  
Jun-15-20 09:20AM  
May-29-20 12:00PM  
May-26-20 08:51AM  
May-21-20 04:06PM  
May-09-20 10:00PM  
May-07-20 04:01PM  
Apr-30-20 12:34PM  
Apr-28-20 08:00AM  
Apr-22-20 12:00PM  
Apr-16-20 05:26PM  
Apr-15-20 05:08PM  
Apr-01-20 03:30PM  
Mar-07-20 12:26AM  
Feb-29-20 07:38AM  
Feb-20-20 12:31PM  
Feb-18-20 01:48PM  
Feb-11-20 12:30PM  
Jan-13-20 01:00AM  
Jan-03-20 04:01PM  
Dec-24-19 01:08PM  
Dec-08-19 03:00PM  
Dec-04-19 11:11AM  
Dec-02-19 10:08AM  
Nov-25-19 09:08PM  
Nov-18-19 10:04AM  
Nov-08-19 04:30PM  
Nov-07-19 06:25PM  
Nov-04-19 07:45AM  
Oct-31-19 10:34AM  
Oct-28-19 06:15PM  
Oct-17-19 08:00AM  
Oct-03-19 08:00AM  
Sep-19-19 08:00AM  
Sep-18-19 10:20AM  
Aug-14-19 09:00PM  
Aug-12-19 12:48PM  
Aug-09-19 02:24AM  
Aug-08-19 06:05PM  
Aug-05-19 12:18PM  
Aug-01-19 10:33AM  
Jul-15-19 02:15PM  
Jul-08-19 08:30AM  
Jun-19-19 03:41PM  
May-24-19 12:45PM  
May-22-19 12:56PM  
May-10-19 01:23PM  
May-09-19 06:05PM  
May-08-19 04:05PM  
May-02-19 10:32AM  
Apr-26-19 11:44AM  
Apr-16-19 12:09PM  
Apr-05-19 07:22PM  
Mar-08-19 03:38PM  
Mar-01-19 07:48AM  
Feb-26-19 08:25AM  
Feb-21-19 07:28AM  
Feb-19-19 08:05PM  
Feb-12-19 10:30AM  
Feb-08-19 07:50AM  
Feb-05-19 04:03PM  
Jan-02-19 04:48PM  
Dec-26-18 10:36AM  
Nov-27-18 07:12AM  
Nov-09-18 07:45AM  
Nov-06-18 06:15PM  
Oct-30-18 10:33AM  
Oct-17-18 04:51PM  
Oct-15-18 09:20AM  
Oct-08-18 08:53AM  
Sep-27-18 04:01PM  
Aug-19-18 11:45PM  
Aug-08-18 07:45AM  
Aug-07-18 07:50AM  
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. It offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms, as well as yeast. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUMPHRIES ROMNEYChief Scientific OfficerJun 18Option Exercise5.933,00017,7903,000Jun 22 07:26 PM
HUMPHRIES ROMNEYChief Scientific OfficerJun 18Sale12.003,00036,0000Jun 22 07:26 PM
HUMPHRIES ROMNEYChief Scientific OfficerJun 17Option Exercise5.932,00011,8602,000Jun 22 07:26 PM
HUMPHRIES ROMNEYChief Scientific OfficerJun 17Sale11.752,00023,5000Jun 22 07:26 PM
HUMPHRIES ROMNEYChief Scientific OfficerJun 16Option Exercise5.934,00023,7204,000Jun 22 07:26 PM
HUMPHRIES ROMNEYChief Scientific OfficerJun 16Sale11.004,00044,0000Jun 22 07:26 PM
SCHULER JACK WDirectorJun 15Buy9.8695,492941,55116,603,524Jun 17 03:30 PM
SCHULER JACK WDirectorJun 12Buy9.34134,0801,252,30716,508,032Jun 16 03:32 PM
SCHULER JACK WDirectorJun 11Buy9.18129,0001,184,22016,373,952Jun 15 03:35 PM
SCHULER JACK WDirectorJun 10Buy9.84100,000984,00016,244,952Jun 12 03:28 PM
SCHULER JACK WDirectorJun 09Buy9.63180,9551,742,59716,144,952Jun 11 03:36 PM
SCHULER JACK WDirectorJun 05Buy8.581,100,0009,438,00015,963,997Jun 09 02:49 PM
SCHULER JACK WDirectorMay 13Buy9.4689,055842,46014,863,997May 15 04:21 PM
SCHULER JACK WDirectorMay 12Buy9.9220,000198,40014,774,942May 14 03:39 PM
SCHULER JACK WDirectorMay 11Buy9.9920,000199,80014,754,942May 13 03:18 PM
SCHULER JACK WDirectorMay 07Buy9.8725,000246,75014,734,942May 11 03:44 PM
SCHULER JACK WDirectorMay 06Buy10.0010,868108,68014,709,942May 08 03:00 PM
SCHULER JACK WDirectorMay 05Buy10.008,62586,25014,699,074May 07 04:19 PM
SCHULER JACK WDirectorMay 04Buy9.981,20412,01614,690,449May 06 03:29 PM
SCHULER JACK WDirectorMay 01Buy10.034,00040,12014,689,245May 05 03:21 PM
SCHULER JACK WDirectorApr 24Buy10.005,00150,01014,685,245Apr 28 03:40 PM
SCHULER JACK WDirectorApr 23Buy9.9081,621808,04814,680,244Apr 27 03:25 PM
SCHULER JACK WDirectorApr 22Buy9.47157,6881,493,30514,598,623Apr 24 03:39 PM
SCHULER JACK WDirectorApr 21Buy9.0179,650717,64714,440,935Apr 23 03:36 PM
SCHULER JACK WDirectorApr 20Buy9.4059,357557,95614,361,285Apr 22 03:17 PM
SCHULER JACK WDirectorMar 31Buy8.30120,000996,00014,301,928Apr 02 03:17 PM
SCHULER JACK WDirectorMar 30Buy8.5980,000687,20014,181,928Apr 01 05:09 PM
SCHULER JACK WDirectorMar 27Buy8.09101,963824,88114,101,928Mar 31 03:12 PM
SCHULER JACK WDirectorMar 26Buy8.04148,0371,190,21713,999,965Mar 30 03:31 PM
SCHULER JACK WDirectorMar 25Buy7.70150,0001,155,00013,851,928Mar 27 09:32 PM
PATIENCE JOHNDirectorMar 24Buy6.835,00034,1504,196,211Mar 26 03:35 PM
SCHULER JACK WDirectorMar 23Buy5.89172,9001,018,38113,551,928Mar 25 03:30 PM
REICHLING STEVENChief Financial OfficerMar 19Buy6.921,0006,92013,300Mar 19 04:05 PM
Strobeck MatthewDirectorMar 18Buy7.1110,00071,100148,235Mar 20 12:31 PM
REICHLING STEVENChief Financial OfficerFeb 27Option Exercise2.9810,00029,80012,300Mar 02 04:55 PM
BIOL BIOLASE, Inc. daily Stock Chart
Index- P/E- EPS (ttm)-0.69 Insider Own27.02% Shs Outstand92.19M Perf Week-8.23%
Market Cap26.87M Forward P/E- EPS next Y-0.09 Insider Trans-20.31% Shs Float83.94M Perf Month-14.41%
Income-19.80M PEG- EPS next Q-0.06 Inst Own8.60% Short Float0.61% Perf Quarter-42.30%
Sales26.50M P/S1.01 EPS this Y28.40% Inst Trans-33.61% Short Ratio0.07 Perf Half Y-46.11%
Book/sh0.03 P/B9.52 EPS next Y70.00% ROA-70.30% Target Price- Perf Year-70.74%
Cash/sh0.06 P/C4.98 EPS next 5Y20.00% ROE- 52W Range0.21 - 1.07 Perf YTD-48.33%
Dividend- P/FCF- EPS past 5Y19.20% ROI-112.90% 52W High-73.31% Beta1.78
Dividend %- Quick Ratio0.50 Sales past 5Y-4.50% Gross Margin36.50% 52W Low35.36% ATR0.03
Employees157 Current Ratio1.10 Sales Q/Q-84.70% Oper. Margin-65.20% RSI (14)33.28 Volatility9.36% 9.74%
OptionableNo Debt/Eq12.77 EPS Q/Q69.40% Profit Margin-74.50% Rel Volume0.41 Prev Close0.28
ShortableYes LT Debt/Eq2.38 EarningsAug 13 AMC Payout- Avg Volume7.26M Price0.29
Recom1.70 SMA20-4.82% SMA50-23.47% SMA200-41.70% Volume3,023,557 Change0.28%
Jun-19-19Initiated The Benchmark Company Speculative Buy $2
Apr-25-17Initiated Singular Research Buy $2.50
May-13-14Downgrade WallachBeth Buy → Hold $4 → $2.50
Nov-12-13Reiterated WallachBeth Buy $3.50 → $2.75
Aug-08-13Reiterated WallachBeth Buy $6.50 → $4.50
Jun-17-13Initiated WallachBeth Buy $6.50
Mar-18-13Reiterated Northland Capital Outperform $6 → $7
Mar-07-13Reiterated Northland Capital Outperform $6 → $7
Sep-07-12Initiated Northland Securities Outperform $4
Sep-15-20 08:30AM  
Sep-11-20 04:05PM  
Sep-03-20 08:30AM  
Aug-24-20 06:30AM  
Aug-18-20 06:30AM  
Aug-13-20 04:05PM  
Aug-11-20 04:43PM  
Jul-22-20 04:05PM  
Jul-16-20 06:30AM  
Jul-13-20 08:00AM  
Jul-09-20 06:30AM  
Jul-08-20 09:00AM  
Jul-02-20 06:30AM  
Jun-22-20 06:30AM  
Jun-11-20 06:30AM  
Jun-08-20 11:00AM  
May-25-20 04:27PM  
May-19-20 06:31AM  
May-10-20 08:36AM  
May-05-20 09:00AM  
Apr-16-20 06:47PM  
Apr-08-20 05:24PM  
Mar-31-20 06:30AM  
Mar-29-20 08:47AM  
Mar-26-20 04:05PM  
Mar-24-20 09:00AM  
Mar-19-20 02:30PM  
Mar-18-20 04:05PM  
Mar-12-20 04:05PM  
Jan-21-20 05:47AM  
Dec-09-19 09:00AM  
Nov-28-19 09:15PM  
Nov-26-19 06:30AM  
Nov-15-19 06:30AM  
Nov-06-19 04:05PM  
Oct-31-19 05:00PM  
Oct-24-19 09:35PM  
Oct-23-19 09:00AM  
Oct-21-19 07:00AM  
Oct-15-19 09:00AM  
Aug-28-19 07:30AM  
Aug-18-19 10:28PM  
Aug-08-19 04:05PM  
Aug-05-19 07:00AM  
Jul-08-19 09:13AM  
Jul-05-19 09:25AM  
May-29-19 04:05PM  
May-24-19 04:10PM  
May-16-19 07:58AM  
May-09-19 06:12PM  
May-06-19 07:00AM  
Apr-27-19 12:53PM  
Apr-09-19 08:00AM  
Mar-27-19 08:00AM  
Mar-12-19 08:45AM  
Mar-11-19 07:00AM  
Mar-08-19 01:48PM  
Mar-05-19 04:05PM  
Feb-28-19 08:00AM  
Feb-07-19 07:00AM  
Feb-04-19 08:00AM  
Jan-29-19 08:00AM  
Jan-03-19 11:11PM  
Dec-21-18 08:00AM  
Nov-29-18 08:00AM  
Nov-26-18 07:00AM  
Nov-13-18 07:19AM  
Nov-01-18 11:43AM  
Oct-29-18 08:00AM  
Oct-09-18 07:00AM  
Sep-25-18 08:00AM  
Sep-19-18 08:30AM  
Sep-12-18 08:00AM  
Sep-05-18 10:02AM  
Aug-22-18 08:30AM  
Aug-14-18 08:00AM  
Aug-08-18 09:40AM  
Aug-01-18 08:30AM  
Jul-26-18 08:00AM  
Jul-11-18 08:00AM  
Jun-26-18 03:59PM  
Jun-19-18 08:00AM  
Jun-05-18 08:00AM  
May-31-18 07:40AM  
May-30-18 08:00AM  
May-10-18 06:00AM  
May-09-18 08:00AM  
May-02-18 06:21PM  
BIOLASE, Inc., together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, such as cosmetic, restorative, and complex surgical applications. The company offers Waterlase all-tissue dental laser systems for cutting soft and hard tissues; diode laser systems to perform soft tissue, hygiene, cosmetic procedures, and teeth whitening, as well as to provide temporary pain relief; and Epic Hygiene laser to manage non-surgical periodontitis and enhance clinical production. It also manufactures and sells consumable products and accessories for its laser systems, as well as markets flexible fibers and hand pieces, and teeth whitening gel kits. The company sells its products through its field sales force and distributor network. The company was formerly known as BIOLASE Technology, Inc. and changed its name to BIOLASE, Inc. in 2012. BIOLASE, Inc. was founded in 1984 and is headquartered in Irvine, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FEINBERG LARRY N10% OwnerJun 09Sale0.551,770,312976,0100Jun 10 05:05 PM
FEINBERG LARRY N10% OwnerJun 08Sale0.553,402,9381,885,908264,141Jun 10 05:05 PM
SCHULER JACK W10% OwnerFeb 11Sale0.601,307,931784,759739,820May 15 04:30 PM
FEINBERG LARRY N10% OwnerOct 29Buy57.5017,391999,98312,765Oct 31 09:21 PM
YTEN Yield10 Bioscience, Inc. daily Stock Chart
Yield10 Bioscience, Inc.
Index- P/E- EPS (ttm)-21.35 Insider Own0.60% Shs Outstand1.96M Perf Week1.53%
Market Cap19.47M Forward P/E- EPS next Y-2.97 Insider Trans- Shs Float1.85M Perf Month65.24%
Income-14.20M PEG- EPS next Q-0.95 Inst Own5.40% Short Float2.40% Perf Quarter4.57%
Sales0.80M P/S24.34 EPS this Y4.00% Inst Trans-0.69% Short Ratio0.03 Perf Half Y73.87%
Book/sh4.33 P/B1.69 EPS next Y36.90% ROA-104.30% Target Price- Perf Year-68.42%
Cash/sh3.20 P/C2.29 EPS next 5Y0.00% ROE-347.90% 52W Range3.50 - 31.05 Perf YTD6.71%
Dividend- P/FCF- EPS past 5Y- ROI521.00% 52W High-76.42% Beta2.22
Dividend %- Quick Ratio6.10 Sales past 5Y-22.00% Gross Margin- 52W Low109.14% ATR0.70
Employees25 Current Ratio6.10 Sales Q/Q-33.30% Oper. Margin- RSI (14)60.44 Volatility8.57% 11.10%
OptionableNo Debt/Eq0.00 EPS Q/Q84.70% Profit Margin- Rel Volume0.06 Prev Close7.31
ShortableNo LT Debt/Eq0.00 EarningsAug 11 AMC Payout- Avg Volume1.28M Price7.32
Recom1.50 SMA2021.46% SMA5022.25% SMA20020.33% Volume82,435 Change0.14%
Sep-10-20Initiated H.C. Wainwright Buy $25
Aug-27-20Upgrade National Securities Neutral → Buy $15
Nov-18-19Downgrade National Securities Buy → Neutral
May-31-19Resumed Maxim Group Buy
Jul-12-18Initiated Maxim Group Buy $7
Sep-10-20 09:31AM  
Sep-09-20 08:30AM  
Aug-27-20 09:00AM  
Aug-26-20 01:00PM  
Aug-22-20 09:30PM  
Aug-21-20 04:22PM  
Aug-17-20 02:18PM  
Aug-11-20 04:05PM  
Aug-06-20 08:30AM  
Aug-05-20 08:30AM  
Aug-04-20 08:30AM  
Jun-17-20 08:30AM  
May-18-20 10:35AM  
May-14-20 04:15PM  
May-13-20 08:30AM  
May-06-20 08:30AM  
Apr-27-20 08:30AM  
Mar-23-20 09:22AM  
Mar-19-20 04:04PM  
Mar-12-20 08:30AM  
Mar-11-20 09:28AM  
Mar-10-20 08:30AM  
Feb-13-20 08:30AM  
Jan-31-20 01:30PM  
Jan-16-20 09:32AM  
Jan-15-20 12:15PM  
Jan-09-20 02:42PM  
Dec-09-19 01:19PM  
Nov-28-19 11:02PM  
Nov-19-19 05:35PM  
Nov-15-19 08:20AM  
Nov-12-19 08:30AM  
Nov-05-19 08:30AM  
Oct-23-19 08:30AM  
Oct-11-19 01:09PM  
Oct-04-19 08:30AM  
Sep-04-19 11:25AM  
Aug-19-19 08:30AM  
Aug-12-19 04:05PM  
Aug-06-19 08:30AM  
Aug-05-19 08:30AM  
Aug-01-19 08:30AM  
Jul-18-19 01:11PM  
Jul-08-19 06:19AM  
Jun-24-19 08:30AM  
Jun-17-19 08:30AM  
May-28-19 08:30AM  
May-09-19 04:05PM  
May-08-19 08:30AM  
May-07-19 05:45AM  
May-01-19 08:30AM  
Apr-23-19 08:30AM  
Apr-16-19 06:49AM  
Apr-11-19 11:01AM  
Apr-10-19 09:07AM  
Apr-02-19 08:00AM  
Mar-28-19 06:48PM  
Mar-25-19 04:02PM  
Mar-21-19 08:30AM  
Mar-19-19 08:30AM  
Mar-15-19 09:00AM  
Feb-26-19 11:28AM  
Jan-22-19 08:30AM  
Jan-15-19 08:30AM  
Dec-13-18 08:30AM  
Nov-28-18 10:37AM  
Nov-08-18 04:02PM  
Oct-30-18 08:30AM  
Oct-02-18 08:00AM  
Sep-25-18 08:30AM  
Sep-21-18 08:30AM  
Sep-19-18 12:25PM  
Sep-10-18 08:30AM  
Sep-05-18 08:00AM  
Aug-28-18 08:30AM  
Aug-09-18 04:05PM  
Aug-08-18 08:30AM  
Aug-02-18 08:30AM  
Jul-17-18 08:00AM  
Jul-11-18 08:30AM  
Jul-02-18 08:30AM  
Jun-21-18 08:30AM  
May-29-18 08:30AM  
May-25-18 03:13PM  
May-23-18 09:00AM  
May-22-18 08:30AM  
May-10-18 04:05PM  
Yield10 Bioscience, Inc., an agricultural bioscience company, engages in developing disruptive technologies for step-changing improvements in crop yield in the United States and Canada. The company, through its Trait Factory, is involved in developing high value seed traits for the agriculture and food industries. It also has an oilseed development center in Saskatchewan, Canada. Yield10 Bioscience, Inc. has research agreements with Bayer AG to develop traits in soybean; Forage Genetics International, LLC to develop traits in forage sorghum; J. R. Simplot Company to develop novel traits in potato; and GDM Seeds Inc. to evaluate yield traits in soybeans. The company was formerly known as Metabolix, Inc. and changed its name to Yield10 Bioscience, Inc. in January 2017. Yield10 Bioscience, Inc. was founded in 1992 and is headquartered in Woburn, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHULER JACK W10% OwnerAug 26Buy4.25365,2411,552,274793,635Aug 31 07:00 AM
SCHULER JACK W10% OwnerFeb 11Sale7.6942,697328,225428,396Feb 12 05:08 PM
SCHULER JACK W10% OwnerFeb 10Buy7.919,85277,880489,496Feb 12 05:08 PM
SCHULER JACK W10% OwnerFeb 10Sale7.9028,256223,180471,093Feb 12 05:08 PM
Peoples Oliver PPres & CEOOct 02Buy0.5382243667,628Oct 02 06:18 PM
Peoples Oliver PPres & CEOOct 01Buy0.569,1785,14066,806Oct 02 06:18 PM